Literature DB >> 7037152

Adriamycin combinations in advanced breast cancer. A Southwest Oncology Group Study.

B L Tranum, B McDonald, T Thigpen, C Vaughn, H Wilson, T Maloney, J Costanzi, J Bickers, N G el Mawli, R Palmer, B Hoogstraten, L Heilburn, S Rasmusen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7037152     DOI： 10.1002/1097-0142(19820301)49:5<835::aid-cncr2820490502>3.0.co;2-z

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  11 in total

Review 1.  Current status of chemotherapy of breast cancer.

Authors:  A Coates
Journal:  Drugs       Date:  1984-08       Impact factor: 9.546

2.  Possible adverse effect of failed adjuvant chemotherapy on the prognosis of women receiving consecutive chemotherapy for recurrent breast cancer.

Authors:  C Dittrich; R Jakesz; K Pirich; L Havelec; G Steger; O Schlappack; R Kolb; K Moser
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

3.  Short term high density systemic therapy for metastatic breast cancer.

Authors:  D C Tormey; J C Kline; M Palta; T E Davis; R R Love; P P Carbone
Journal:  Breast Cancer Res Treat       Date:  1985       Impact factor: 4.872

4.  Combination chemotherapy with 5-fluorouracil, oral Idarubicin, and cyclophosphamide (FIC) in metastatic breast cancer--an open phase II study.

Authors:  K Kolarić; V Potrebica; D Vukas; Z Mechl; B Sopkova
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

5.  Feasibility and pharmacokinetics of combined therapy with S-1 and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic or recurrent breast cancer.

Authors:  Yasuhiro Suzuki; Rin Ogiya; Risa Oshitanai; Mayako Terao; Mizuho Terada; Toru Morioka; Banri Tsuda; Naoki Niikura; Takuho Okamura; Yuki Saito; Yutaka Tokuda
Journal:  Int J Clin Oncol       Date:  2013-04-05       Impact factor: 3.402

6.  Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944).

Authors:  G G Kimmick; C Cirrincione; D B Duggan; K Bhalla; N Robert; D Berry; L Norton; S Lemke; I C Henderson; C Hudis; E Winer
Journal:  Breast Cancer Res Treat       Date:  2008-02-28       Impact factor: 4.872

7.  Hepatic arterial infusion chemotherapy for liver metastases from breast cancer.

Authors:  Y Arai; Y Sone; Y Inaba; Y Ariyoshi; C Kido
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 8.  Chemotherapy of breast cancer.

Authors:  L S Perlow; J F Holland
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

9.  High-dose epirubicin as primary chemotherapy in advanced breast carcinoma: a phase II study.

Authors:  J Carmo-Pereira; F O Costa; D W Miles; E Henriques; M A Richards; R D Rubens
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

10.  Combination chemotherapy with oral idarubicin and cyclophosphamide for metastatic breast cancer.

Authors:  M Lopez; P Vici; S Carpano; M Natali; F Ganzina; E M Conti; L Di Lauro
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.